AED | Audio Epilepsy Digest

Episode 6: From Random Seizures to Risk States

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.Episode 6: From Random Seizures to Risk StatesThis monthly special asks whether seizure timing is moving from clinical randomness toward individualized, time-varying risk states.The episode covers recent work on epilepsy chronobiology, seizure cycles, past-only forecasting pipelines, chance-model pitfalls, diary and wearable approaches, home EEG feasibility, sleep-drive physiology, and computational medication-timing models.The practical message is restrained: seizure timing is becoming a serious clinical-research variable, but current evidence supports better questions and better trials more than routine patient-facing forecasts or medication-timing changes.Listen and follow Audio Epilepsy Digest:https://audioepilepsydigest.com/ [https://audioepilepsydigest.com/] AI editorial/source review for this episode:https://audioepilepsydigest.com/episode-006-ai-review.html [https://audioepilepsydigest.com/episode-006-ai-review.html]Key takeaways:- Seizure timing can reflect circadian, sleep-wake, sleep-drive, and multidien risk rhythms, but that does not make seizures reliably predictable for routine care.- Forecasting claims need past-only implementation, meaningful chance models, simple benchmarks, prospective validation, and attention to false alarms and patient burden.- Wearable, diary, and home EEG studies show why the field is plausible, but feasibility and proof of principle are not the same as clinical effectiveness.- Medication-timing models and sleep-drive experiments are useful for hypothesis generation, not patient-specific treatment advice.Papers discussed include:1. Baud MO, et al. "Timing is everything: Expert opinion on researching epilepsy rhythms by the ILAE Task Force on Chronobiology." Epilepsia (2026). PMID: 41483455.2. Yang H, et al. "Seizure forecasting with epilepsy cycles: On the causality of forecasting pipelines." Epilepsia (2026). PMID: 41591752.3. Andrzejak RG, et al. "Are seizure forecasts and cycles better than chance? What chance?" Epilepsia (2026). PMID: 41783988.4. Chang CY, et al. "Rigorous evaluation of five models for e-diary-only seizure forecasting-retrospective and prospective datasets do not outperform the Napkin method." Epilepsia (2026). PMID: 41085335.5. Xiong W, et al. "Forecasting seizure likelihood from cycles of self-reported events and heart rate: a prospective pilot study." eBioMedicine (2023). PMID: 37331164.6. Cuddapah VA, et al. "Sleep drive, not total sleep amount, increases seizure risk." Nature Communications (2025). PMID: 40730814.Caveats:- Forecasting remains probabilistic and research-stage.- The sleep-drive source is preclinical and should not be treated as human sleep advice.- Medication-timing modeling is not a recommendation to change antiseizure medication schedules.- Home EEG feasibility and forecasting protocols do not yet prove clinical effectiveness.

Episode 5: Cognition Is Becoming Actionable

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes. Episode 5: Cognition Is Becoming Actionable Are recent studies moving epilepsy cognition from a recognized comorbidity to a measurable and partly modifiable care target? This episode of Audio Epilepsy Digest looks at four recent Neurology and Epilepsia papers on sleep, cognitive phenotyping, psychosocial rehabilitation, and dementia-plus-epilepsy medication safety. The practical message is cautious but useful: cognition in epilepsy is becoming easier to measure and partly more actionable, but the evidence does not prove that sleep treatment prevents dementia or that rehabilitation restores objective memory. Listen and follow Audio Epilepsy Digest:https://audioepilepsydigest.com/ AI editorial/source review for this episode:https://audioepilepsydigest.com/episode-005-ai-review.html Key takeaways: - In focal epilepsy, nonoptimal self-reported sleep was associated with worse executive function and higher dementia-risk signal, but causality remains unproven. - IC-CoDE is research infrastructure for reproducible cognitive phenotyping, not a clinical decision tool. - Cognitive and psychosocial rehabilitation improved quality of life and anxiety more clearly than objective delayed recall. - In dementia plus epilepsy, first ASM survival associations are clinically important but still registry-based and vulnerable to residual confounding. Papers discussed: 1. Tai XY, et al. "The Relationship Between Sleep, Cognition, and Dementia Risk in People With Focal Epilepsy." Neurology (2026). PMID: 42018962. 2. Brunger T, et al. "The International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) Portal: An open source resource for neuropsychological research in epilepsy." Epilepsia (2026). PMID: 42095829. 3. Mameniskiene R, et al. "Rehabilitation of cognition and psychosocial well-being in epilepsy: Results of a randomized waiting list-controlled trial." Epilepsia (2026). PMID: 41984512. 4. Zelano J, et al. "Differences in Survival Associated With the First Antiseizure Medication in People With Dementia and Epilepsy." Neurology (2026). PMID: 41996657. Source review note:This episode went through AED's automatic two-reviewer source review. Both reviewers cleared the episode with minor caveats before human audio QA. Caveats: - Sleep duration in Tai et al. was self-reported and observational. - IC-CoDE should not be used for individual clinical decision-making. - The rehabilitation trial supports patient-reported benefit more strongly than objective cognitive improvement. - Zelano et al. should be read as association, not causal ASM ranking.

Episode 4: Drug-Resistant Epilepsy in 2026

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes. Episode 4: Drug-Resistant Epilepsy in 2026 Does the pathway after two failed antiseizure medications still end in surgery? This episode of Audio Epilepsy Digest looks at the 2026 drug-resistant epilepsy treatment pathway through cenobamate surgery-timing data, the FRANCE anterior thalamic DBS trial, and emerging intracranial biomarker work. The practical message is coexistence, not replacement. Cenobamate may change timing for selected patients, surgical evaluation still matters when a structural target is plausible, ANT-DBS remains palliative rather than curative, and biomarkers are promising research tools rather than current pathway arbiters. Listen and follow Audio Epilepsy Digest: https://audioepilepsydigest.com/ AI editorial/source review for this episode: https://audioepilepsydigest.com/episode-004-ai-review.html Key takeaways: - Pellinen's cenobamate findings are a single-center association in a selected subgroup, not proof that medication replaces surgery.- Kerr and McFarlane frame the key distinction: surgical delay is not the same as surgical obviation. - FRANCE suggests potential benefit for ANT-DBS in a highly refractory VNS-failed cohort, but it did not prove superiority over best medical therapy. - Aiello's ANT spectral biomarkers are hypothesis-generating and require prospective validation before clinical programming use. Papers discussed: 1. Pellinen J, et al. "Delayed and deferred surgery associated with cenobamate use in people with drug-resistant focal epilepsy." Epilepsia (2026). PMID: 41885758. 2. Kerr WT, McFarlane KN. "Redefining the treatment pathway for medication-resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay." Epilepsia (2026). PMID: 41972812. 3. Chabardes S, et al. "Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial." Epilepsia (2026). PMID: 41902639. 4. Aiello G, et al. "Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study." Brain (2026). PMID: 41934257. Source review note:This episode went through AED's automatic two-reviewer source review and regeneration loop. Earlier drafts were rejected or revised before this version cleared with minor caveats. Caveats: - Disparity mechanisms discussed around surgical timing should be understood as hypotheses, not findings directly tested by Pellinen. - Quality of life in FRANCE is multifactorial; palliative seizure-burden reduction should not be treated as equivalent to seizure freedom. - Cenobamate claims should remain anchored to Pellinen's selected subgroup and single-center retrospective design.

Episode 3: Epilepsy Care Beyond the Seizure Count

> **NOTE:** This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. > If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes. ## Episode Summary What should epilepsy care measure when seizure counts are not enough? This episode of *Audio Epilepsy Digest* looks at four recent epilepsy papers that widen the frame beyond seizure frequency. The studies move across respiratory physiology, at-home EEG monitoring, patient-facing seizure terminology, and the lived burden of epilepsy for patients and caregivers. The common thread is measurement humility. Seizure counts remain essential, but they do not capture the whole clinical problem. Better epilepsy measurement will need to integrate physiology, cognition and consciousness, real-world monitoring, patient-reported burden, and caregiver effects while staying honest about what is still research-grade rather than practice-changing. ## Key Takeaways - Respiratory physiology may become an important risk-signal domain, but the current respiratory-variability study should not be heard as a validated individual SUDEP prediction tool. - At-home EEG self-monitoring appears feasible for selected, supported patients, but it does not replace routine EEG, ambulatory EEG, EMU evaluation, or expert interpretation. - Patient-facing definitions of ictal impairment of consciousness can be understandable, but terminology comprehension is not the same as proof of improved clinical outcomes. - Patient-burden research reinforces that seizure counts miss mood symptoms, fatigue, sleep disruption, productivity effects, and caregiver burden, while the current survey remains selected and descriptive. ## Papers Discussed 1. Caplan R, et al. “Association of Interictal Respiratory Variability and Severity of Postictal Hypoxemia After Generalized Convulsive Seizures.” *Neurology* (2026). PMID: 41805401. PMCID: PMC13034677. 2. Cousyn L, et al. “Out of the lab, into real life: Evaluating at-home EEG self-monitoring.” *Epilepsia Open* (2026). PMID: 41701004. PMCID: PMC13052238. 3. Marcinski Nascimento D, et al. “Persons with epilepsy and their caregivers understand the definition of ictal impairment of consciousness.” *Epilepsia* (2026). PMID: 41705916. PMCID: PMC13075620. 4. Wagner S, et al. “What does it mean to live with epilepsy? Burden of illness from the patient perspective.” *Epilepsia Open* (2026). PMID: 41770623. PMCID: PMC13052003. ## Source Review This episode went through AED’s transcript-first AI-assisted source review process. The generated audio was transcribed, checked against the full-text source packet, and forced through a pass/revise/regenerate gate. Two earlier audio candidates were rejected before this version cleared AI source review with minor caveats and then passed human audio QA. Read the AI-review note: https://erafat.github.io/audio-epilepsy-digest/episode-003-ai-review.html [https://erafat.github.io/audio-epilepsy-digest/episode-003-ai-review.html] Listen and follow: https://erafat.github.io/audio-epilepsy-digest/AI editorial/ [https://erafat.github.io/audio-epilepsy-digest/AI editorial/] ## Caveats - The respiratory paper supports association and biomarker potential, not individual-level SUDEP prediction. - The home EEG paper supports feasibility in selected, supported patients. Interictal epileptiform discharge concordance with prior in-hospital recordings was reported for three of the four IED-positive participants, but this should not be generalized into replacement of standard clinical EEG workflows. - The terminology paper supports comprehension of a proposed definition, not downstream outcome improvement. - The burden-of-illness paper is descriptive and selected. PHQ-9 and GAD-7 findings are screening results, not formal diagnoses, and the survey does not establish treatment status, mechanism, or medication causality.

Episode 2: What Seizure Counts Miss

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes. ## Description What changes in epilepsy care when we widen the lens beyond raw seizure counts? This episode of Audio Epilepsy Digest looks at four blind spots that appear when epilepsy care is organized too narrowly around seizure counts: etiologic workup after pediatric status epilepticus, early cognitive burden in newly diagnosed focal epilepsy, drug-specific dose logic in idiopathic generalized epilepsy, and the outcome measures used to judge rescue therapy in seizure clusters. The through-line is simple: the right clinical question changes with the problem in front of us. Sometimes the missed issue is genetics. Sometimes it is four-week verbal retention rather than 30-minute recall. Sometimes it is whether escalating lamotrigine is still doing useful work. And sometimes it is whether a rescue medication should be judged by chronic seizure freedom or by the interval between treated clusters. Topics covered: - when pediatric status epilepticus should prompt a stronger genetics-first lens - what the accelerated long-term forgetting paper actually shows, and what it does not, about early memory burden - why ASM dose-response should remain drug-specific rather than assumed to be uniform - why the diazepam nasal spray SEIVAL paper matters more for endpoint design and counseling than for immediate prescribing ## Key Takeaways - Pediatric status epilepticus should trigger earlier and more systematic thinking about genetic evaluation, especially in younger children and mixed focal-generalized phenotypes. - The accelerated long-term forgetting signal in newly diagnosed focal epilepsy is task-specific: story memory and verbal recognition look more vulnerable than a blanket all-domain memory model would suggest. - Dose escalation in generalized epilepsy should remain drug-specific rather than assumed to be monotonic across all ASMs, with the strongest practical caution in this cohort applying to lamotrigine doses above the moderate range. - Rescue-medication effectiveness may be better captured by seizure-interval change than by endpoints borrowed from chronic maintenance treatment, but the current SEIVAL paper is best heard as endpoint-development work rather than practice-changing efficacy proof. ## Sources 1. Marini C, Rosati A, Fusco L, et al. *Neurology* (2026). PMID: 41915870. 2. Jackson CF, Makin SM, Mohanraj R, et al. *Epilepsy & Behavior* (2026). PMID: 41707288. 3. Abdullah-Roskjær A, Gesche J, Rubboli G, Beier CP. *Epilepsy & Behavior* (2026). PMID: 41707289. 4. Kerr WT, McFarlane KN, Ngo LY, et al. *Epilepsia* (2026). PMID: 41919765. ## Caveats - The selected papers pull in different practice domains, so the episode is a synthesis rather than a single tightly focused controversy packet. - Some conclusions remain provisional and should be heard in light of study design limitations and generalizability constraints. - The diazepam paper is a post hoc open-label reanalysis with industry funding, an internal baseline, and unmeasured longitudinal confounding. - The IGE dosing paper is retrospective, uses self-reported seizure outcomes, and does not model combination therapy or serum levels cleanly. - The ALF paper is small and task-specific, so its main value is sharpening how we talk about early cognitive burden rather than defining a broad screening protocol.